[go: up one dir, main page]

SG11201606652PA - Solid forms of an ion channel modulator - Google Patents

Solid forms of an ion channel modulator

Info

Publication number
SG11201606652PA
SG11201606652PA SG11201606652PA SG11201606652PA SG11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA
Authority
SG
Singapore
Prior art keywords
ion channel
solid forms
channel modulator
modulator
solid
Prior art date
Application number
SG11201606652PA
Inventor
Anna Chiu
Olga V Lapina
Petinka I Vlahova
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201606652PA publication Critical patent/SG11201606652PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201606652PA 2014-02-13 2015-02-12 Solid forms of an ion channel modulator SG11201606652PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939640P 2014-02-13 2014-02-13
PCT/US2015/015652 WO2015123434A1 (en) 2014-02-13 2015-02-12 Solid forms of an ion channel modulator

Publications (1)

Publication Number Publication Date
SG11201606652PA true SG11201606652PA (en) 2016-09-29

Family

ID=52597268

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606652PA SG11201606652PA (en) 2014-02-13 2015-02-12 Solid forms of an ion channel modulator

Country Status (16)

Country Link
US (1) US9273038B2 (en)
EP (1) EP3105227A1 (en)
JP (1) JP2017505788A (en)
KR (1) KR20160118358A (en)
CN (1) CN105980380A (en)
AR (1) AR102804A1 (en)
AU (1) AU2015217129A1 (en)
BR (1) BR112016018464A2 (en)
CA (1) CA2881544A1 (en)
EA (1) EA201691360A1 (en)
HK (1) HK1226397A1 (en)
IL (1) IL246959A0 (en)
MX (1) MX2016010563A (en)
SG (1) SG11201606652PA (en)
TW (1) TW201613908A (en)
WO (1) WO2015123434A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013028886A2 (en) 2011-05-10 2016-08-09 Gilead Sciences Inc fused heterocyclic compounds as sodium channel modulators
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compound as ion channel regulator
NO3175985T3 (en) 2011-07-01 2018-04-28

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
CN102725290B (en) * 2009-07-27 2016-03-09 吉利德科学股份有限公司 As the condensed heterocyclic compouds of ion channel modulators
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compound as ion channel regulator
HK1201455A1 (en) * 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
KR20160118358A (en) 2016-10-11
TW201613908A (en) 2016-04-16
BR112016018464A2 (en) 2017-08-08
WO2015123434A1 (en) 2015-08-20
JP2017505788A (en) 2017-02-23
AR102804A1 (en) 2017-03-29
CN105980380A (en) 2016-09-28
AU2015217129A1 (en) 2016-08-11
MX2016010563A (en) 2016-12-12
CA2881544A1 (en) 2015-08-13
IL246959A0 (en) 2016-09-29
EA201691360A1 (en) 2017-07-31
HK1226397A1 (en) 2017-09-29
US20150225383A1 (en) 2015-08-13
EP3105227A1 (en) 2016-12-21
US9273038B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL259421B (en) Modulators of ror-gamma
EP3183346A4 (en) Channel modulators
EP3169217A4 (en) Channel formation
IL257026A (en) Solid state forms of eluxadoline
EP3127016A4 (en) Provable geo-location
GB201418182D0 (en) Ion modification
SI3845221T1 (en) Solid state forms of sofosbuvir
IL246979A0 (en) Solid state forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
ZA201804342B (en) Channel section
GB201604627D0 (en) Improved method of FT-IMS
GB201418395D0 (en) Cyclo-depolymerisation of polybutadiene
EP3100230A4 (en) Segments of contacts
PL3111151T3 (en) Method of operating an hydraulic-binder rotary-furnace
IL246959A0 (en) Solid forms of an ion channel modulator
IL248999A0 (en) Method of geolocation
GB2535265B (en) Ion source
SG11201600348XA (en) Insulator target
GB2522904B (en) Method of making an airdam
IL250976A0 (en) Broadcast channel testing
SG11201607445QA (en) Methods of modulating wars2
HK1227393A1 (en) Solid forms of an ion channel modulator
PT3377106T (en) Modulation of ciliogenesis
IL249332A0 (en) Solid state forms of sofosbuvir